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The molecular mechanisms underlying primary
glucocorticoid resistance or hypersensitivity are
not well understood. Using transfected COS-1
cells as a model system, we studied gene regula-
tion by naturally occurring mutants of the glu-
cocorticoid receptor (GR) with single-point muta-
tions in the regions encoding the ligand-binding
domain or the N-terminal domain reflecting differ-
ent phenotypic expression. We analyzed the ca-
pacity of these GR variants to regulate transcrip-
tion from different promoters, either by binding
directly to positive or negative glucocorticoid-re-
sponse elements on the DNA or by interfering with
protein-protein interactions. Decreased dexa-
methasone (DEX) binding to GR variants carrying
mutations in the ligand-binding domain correlated
well with decreased capacity to activate transcrip-
tion from the mouse mammary tumor virus (MMTV)
promoter. One variant, D641V, which suboptimally
activated MMTV promoter-mediated transcription,
repressed a PRL promoter element containing a
negative glucocorticoid-response element with
wild type activity. DEX-induced repression of tran-
scription from elements of the intercellular adhe-
sion molecule-1 promoter via nuclear factor-kB by
the D641V variant was even more efficient com-
pared with the wild type GR. We observed a gen-
eral DEX-responsive AP-1-mediated transcrip-
tional repression of the collagenase-1 promoter,
even when receptor variants did not activate tran-
scription from the MMTV promoter. Our findings
indicate that different point mutations in the GR
can affect separate pathways of gene regulation in
a differential fashion, which can explain the various
phenotypes observed. (Molecular Endocrinology
11: 1156–1164, 1997)
INTRODUCTION
In man, response to glucocorticoids may vary consid-
erably. Some individuals are quite sensitive to these
steroid hormones, whereas others are relatively resis-
tant. Hypersensitivity to glucocorticoids may be man-
ifested by the development of cushingoid features af-
ter low-dose treatment (1). In primary glucocorticoid
resistance, negative feedback of cortisol on the hypo-
thalamic-pituitary-adrenal axis is decreased. The set
point of this axis is set at a higher level with higher
plasma concentrations of ACTH and cortisol (2–5). The
diurnal rhythm of cortisol secretion remains intact, and
the system also remains sensitive to external stressors
such as acute hypoglycemia (2, 6). The elevated cor-
tisol levels do not cause signs or symptoms of Cush-
ing’s syndrome, due to reduced response to cortisol in
all target tissues.
In a number of reports, glucocorticoid resistance in
humans has been correlated with mutations in the
gene encoding the glucocorticoid receptor (GR) (7–
10). The receptor is expressed throughout the body
and plays a key role in both positive and negative
regulation of gene expression (11–14). Because glu-
cocorticoids play an important role in normal develop-
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ment and in maintenance of basal and stress-related
homeostasis, including regulation of various metabolic
processes, central nervous system functions, and re-
straint of the inflammatory/immune reaction, altered
GR function may have widespread consequences (2,
15).
Analysis of a number of healthy volunteers indicated
the existence of two N-terminal GR receptor variants
with a normal dissociation constant (16), carrying ei-
ther an arginine to lysine change at position 23 of the
protein (R23K) or an asparagine to serine change at
codon 363 (N363S). In three individuals the R23K vari-
ant was accompanied by signs and symptoms of glu-
cocorticoid resistance, whereas four other individuals
with the same mutation were asymptomatic. The
N363S variant was present in several members of a
family with glucocorticoid resistance. The glucocorti-
coid-resistant members also had a GR gene microde-
letion resulting in functional knock-out of the allele not
containing the mutation. This variant had a normal
capacity to activate transcription in a transfection as-
say (9). It was later reported to be present in two
glucocorticoid-resistant small cell lung tumor cell lines
(17, 18). Our recent studies suggest that the N363S
variant is present in about 6% of the normal Dutch
population and might be accompanied by an in-
creased sensitivity to glucocorticoids (1). Furthermore,
three different variant human GR forms with altered
amino acids in their C termini have been reported to
date: 1) a heterozygous isoleucine to asparagine
change at codon 559 (I559N), which abolished detect-
able ligand binding and was found in a patient who
presented with hypertension and oligospermia (10); 2)
a homozygous aspartic acid to valine change at codon
641 (D641V), the dissociation constant of which was 3
times higher relative to the wild type receptor, occur-
ring in a patient with severe hypertension and hypo-
kalemia (7); and 3) a homozygous valine to isoleucine
change at codon 729 (V729I), with a 2-fold higher
dissociation constant relative to the wild type receptor,
which was found in a young boy with isosexual pre-
cocity as a result of increased levels of adrenal andro-
gens (8). These mutations are indicated in Fig. 1A. No
mutations in the region involved in DNA binding have
yet been reported in humans. The natural, non-ligand-
binding b-isoform of the GR (human GRb), the pres-
ence of which has not yet been related to disease,
does not activate transcription in transfection assays
(9). To obtain more insight into its mode of action, this
isoform has been included in this investigation.
GR acts through several distinct mechanisms to
activate or repress transcription. It can either bind
directly to a specific DNA sequence, termed a positive
or a negative (n) glucocorticoid response element
(GRE) (19, 20), or it can interact with other transcription
factors such as AP-1 (21, 22) and nuclear factor
(NF)-kB (23–25) without itself being bound to DNA. GR
variants may achieve a differential interaction with the
transcription machinery and any of these factors. Fur-
thermore, the abundance and activity of components
of the transcription machinery and the interacting fac-
tors may differ among individuals. As a first step to-
Fig. 1. Human GR Variants and Their Expression
A, Amino acid alterations reported in the hGR associated with glucocorticoid resistance (7, 8, 10, 16). B, Western Immunoblot
analysis of the GR receptor variants. The expression of the indicated receptor variants was measured by transfecting COS-1 cells.
hGRb is a naturally occurring splice variant of the wild type GR (see Refs. 9 and 47). Size markers are b-galactosidase (123 kDa)
and BSA (80 kDa).
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ward explaining more precisely the varying phenotypic
expression of the GR variants in primary glucocorti-
coid resistance, we examined their capacity to acti-
vate or repress transcription from several different pro-
moters in COS-1 cells.
RESULTS
Expression of the Human (h) GR Mutant
Constructs
First, we investigated whether transfection of expres-
sion plasmids containing the different GR variants as
well as the naturally occurring splice variant hGRb
resulted in comparable intracellular levels of receptor
protein. COS-1 cells were used in this and subsequent
experiments because these cells contain little, if any,
endogenous GR protein (Fig. 1B, pTZ control lane).
Immunoblot analysis of lysates from COS-1 cells
transfected with the GR variants showed that all GR
constructs were properly expressed (Fig. 1B).
Activation of Transcription by hGR Variants
The R23K and N363S variants had a capacity to acti-
vate mouse mammary tumor virus (MMTV)-driven
transcription similar to that of the wild type GR (see
Table 1, column MMTV. The potency of the wild type
GR to regulate transcription from the various promot-
ers is set as 1). I559N did not activate transcription
(Ref. 10 and Table 1), whereas the concentration of
dexamethasone (DEX) required for half-maximal stim-
ulation of LUC activity by the V729I variant was 12-fold
higher (Fig. 2), similar to what has been published
previously (8). The overall relative potency of the V729I
variant to activate transcription from the MMTV pro-
moter compared with the wild type GR at the subop-
timal ligand concentrations was 0.08 (Table 1). The
D641V variant was even less potent than the V729I
variant (Fig. 2), with an overall relative potency of 0.04
(Table 1). The hGRb-form, which is known not to ac-
tivate transcription, was used as a negative control
(Fig. 2).
Negative GRE-Mediated Repression of
Transcription by the hGR Variants
An expression construct containing a region of the
PRL promoter designated PRL3 (2247 to 2214), com-
prising an nGRE fused upstream of a thymidine kinase
(tk) promoter-LUC fusion gene (PRL3-tk-LUC), was
cotransfected with the variant GR plasmids. At differ-
ent ligand concentrations, repression of LUC tran-
scription by the receptor variants was determined. In
the presence of 1027 M DEX, the wild type GR re-
pressed transcription by 55% (Fig. 3). The capacity of
the N-terminal variants (R23K and N363S) to repress
transcription was comparable to the wild type GR
(Table 1). The I559N and hGRb variants did not repress
transcription (Table 1). Surprisingly, the D641V variant
Fig. 2. Transcriptional Activation of the MMTV Promoter by
Wild Type GR (M), D641V (E), V729I (), hGRb (F)
Data are the means of two transfections carried out in
triplicate; error bars represent standard deviations of the
mean. Cells were cotransfected each time with the MMTV-
LUC reporter construct and one of the GR expression vectors
encoding the above mentioned variants and were subse-
quently treated with DEX at the indicated concentrations.
Table 1. Relative Potencies of the Various GR Mutants in Regulation of Transcription
Promoter
MMTV PRL-3 ICAM-1 COLL
wtGR 1 1 1 1
R23K 1 1 1 1
N363S 1 1 1 1
I559N Inactive Inactive Inactive 0.002 (3.1025–0.03)a
D641V 0.04 (0.03–0.07)a 0.52 (0.07–2.8)a 4.6 (2.87–7.48)a 0.16 (0.10–0.26)a
V729I 0.08 (0.05–0.13)a 0.95 (0.15–6.6)a 0.3 (0.18–0.48)a 0.12 (0.07–0.19)a
hGRb Inactive Inactive Inactive 0.001 (3.1025–0.01)a
Regulation of transcription by the GR variants at different ligand concentrations as compared to the wild type GR was determined
using parallel line statistics (45).
a 95% confidence limits.
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repressed nearly as efficiently as did the wild type GR
(Fig. 3). The overall relative potency of repression by
D641V was 0.52 (Table 1). V729I, however, did not
repress at 1029 M DEX, whereas the wild type GR and
D641V significantly repressed PRL3-tk-LUC transcrip-
tion to 76% at this concentration (Fig. 3). At higher
ligand concentrations, V729I repressed at wild type
levels with an overall relative potency of 0.95 (Table 1).
Nuclear Factor (NF)-kB Transcriptional
Repression by the hGR Variants
Without added p65 plasmid, the intercellular adhesion
molecule (ICAM)-1 promoter had a basal activity that
could not be repressed by active GR (data not shown),
due to the virtual absence of endogenous NF-kB in
COS-1 cells. A 6-fold induction of ICAM-1-LUC ex-
pression was observed when a p65 expression plas-
mid was cotransfected (data not shown). In the pres-
ence of 1027 M DEX, the wild type GR repressed
p65-induced expression by 57% (Fig. 4). The R23K
and N363S variants repressed to a similar extent as
did the wild type GR, but the I559N variant did not
repress p65-induced expression (Table 1). To study
subtle differences between the capacities of the vari-
ants to inactivate NF-kB, repression of the ICAM 1
promoter was also studied at lower ligand concentra-
tions. The D641V variant repressed better than did the
wild type GR (Fig. 4); the overall relative potency to
repress the ICAM-1 promoter compared with the wild
type GR at the measured ligand concentrations was
4.6 (Table 1). The V729I variant was slightly less effec-
tive compared with the wild type GR (Fig. 4), with a
relative potency value of 0.3 (Table 1). Human GRb did
not repress at all ligand concentrations (Table 1).
Because the D641V variant repressed transcription
from the ICAM-1 promoter more efficiently compared
with the wild type GR, it might interact more efficiently
with the p65 protein to prevent the interaction of the
p65 protein with the ICAM-1 promoter. We studied
repression by lower concentrations of the variants at
1.0 nM DEX, as this ligand concentration was most
discriminative (Fig. 4). At receptor concentrations that
were up to 5 times lower, we observed the same
relative levels of repression of the ICAM-1 promoter
(not shown). C476W/R479Q, an artificial GR variant
that retained its full capacity to bind hormone (21), did
not repress NF-kB activity at all; it even seemed to
increase the activation of the ICAM-1 promoter at
1028 M and 1027 M DEX (Fig. 4).
Repression of AP-1 by the GR Variants
Repression of AP-1-mediated transcription from the
collagenase 2517/163 promoter by the GR variants in
the presence of increasing amounts of DEX was mea-
sured. In the presence of 1027 M DEX, the wild type GR
inactivated AP-1 by 84% (Fig. 5). The R23K and
N363S variants repressed similarly as the wild type GR
(Table 1). The I559N and hGRb variants displayed a
weak, hormone-dependent repression. The I559N
Fig. 3. Transcriptional Repression of PRL3-tk-LUC by the
Wild Type GR (M), D641V (E), and V729I ()
Data are the means of three transfections carried out in
triplicate; error bars represent standard deviations of the
mean. Cells were cotransfected each time with the PRL3-tk-
LUC reporter construct and one of the GR expression vectors
encoding the above mentioned variants and were treated
with the DEX concentrations indicated. The R23K and N363S
variants repressed at wild type levels; the I559N and hGRb
variants did not repress (not shown).
Fig. 4. Transcriptional Repression of p65-Activated ICAM-
1-LUC by the Wild Type GR (M), D641V (E), V729I () and
C476W/R479Q ()
Data are the means of one representative transfection
assay carried out in triplicate; error bars represent standard
deviations of the mean. Cells were cotransfected with the
ICAM-1-LUC reporter construct and the GR expression vec-
tors encoding the variants mentioned above and were treated
with DEX at the concentrations indicated.
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variant repressed by 50% at 1027 M DEX (Fig. 5A) with
an overall relative potency compared with the wild
type GR of 0.002 (Table 1). Human GRb repressed by
40% at 1027 M DEX with an overall relative potency
compared with the wild type GR of 0.001 (Table 1).
The C476W/R479Q variant did not repress, as has
been shown before (21). At 1, 10, and 100 nM DEX, this
variant even induced expression from the collagenase
promoter (Fig. 5B). At 1027 M DEX, the D641V and
V729I variants repressed as efficiently as did the wild
type GR. However, these variants showed a shift in
their dose-response curves (Fig. 5B), with overall
relative potencies of 0.16 and 0.12, respectively
(Table 1).
DISCUSSION
To obtain insight in what might be the functional sig-
nificance of naturally occurring point mutations of the
human GR gene, we set up transfection assays using
different reporter constructs, the promoters of which
were either positively or negatively regulated by GR.
There were no indications for reduced function of
the R23K variant receptor because it activated MMTV
transcription equally well as the wild type GR. The
R23K amino acid substitution is well outside the t1-
region of the transcriptional activation domain, which
ranges from position 77 to 262 of the GR protein as
determined in an in vitro system similar to the one used
here (26); this explains the unaltered in vitro capacity of
this variant to activate transcription. Carriers of the
R23K variant receptor showed a variety of pheno-
types, ranging from asymptomatic to severely glu-
cocorticoid resistant. Thus, the presence of the muta-
tion per se could not be correlated directly with
glucocorticoid resistance (16). If it is a functional mu-
tation, this would imply that at least one additional
factor is involved in the resulting phenotype. Carriers
of the N363S variant receptor showed a significantly
higher increase of peripheral insulin levels in response
to DEX than controls, suggesting increased sensitivity
(1). At present it is not known which molecular mech-
anism underlies this observation.
Different modes of GR-mediated transcriptional re-
pression have been reported (19–25), one of which
requires binding of the receptor to an nGRE (19, 20).
Different nGREs lack extensive homologies, but each
nGRE is related to the GRE consensus element impli-
cated in receptor binding and enhancer activity at
positive GREs (20). The nGRE-bound GR does not
activate, but represses, transcription of the down-
stream gene, as is shown to be the case for the POMC
promoter (19) and the PRL promoter (20). The fact that
the N-terminal amino acid alterations are positioned
outside the t1-region does not necessarily imply that
the capacity of the N-terminal GR variants to repress
transcription by binding to an nGRE is unaltered. It is
well known that the GR DNA-binding domain is in-
volved in nGRE binding (20). The variants tested here
have amino acid alterations residing well outside the
DNA-binding domain. Since the effects of the N-ter-
minal variants on PRL3tkLUC expression and MMTV-
directed transcription did not differ from those of the
wild type GR, there are no indications for disruption of
conformation, or diminished binding to DNA due to the
Fig. 5. Transcriptional Repression of COLL-LUC
A, Wild type GR (M, hGRb (v), I559N (). B, Wild type GR (M), D641V (E), V729I (), C476W/R479Q (). Data are the means
of two transfections carried out in duplicate; error bars represent standard deviations of the mean. Cells were cotransfected with
the COLL-LUC reporter construct and the GR expression vectors and were treated with DEX at the concentrations indicated.
Simultaneously, cells were treated with 1024 M TPA to activate endogenous AP-1.
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altered amino acids. Results of this study suggest that
repression by binding to the PRL nGRE requires hor-
mone binding because the I559N variant, which has a
very low, if any, ligand affinity, completely failed to
repress transcription from the thymidine kinase pro-
moter, most likely as a result of failure of this variant to
translocate into the nucleus. The V729I variant re-
pressed the PRL promoter relatively less efficiently at
low ligand concentrations (Fig. 3), which could be
anticipated from the similarly less efficient transcrip-
tional activation of the MMTV promoter by this variant
(Fig. 2), as both types of gene regulation are mediated
by direct binding of the GR to response elements on
the DNA. The D641V variant (7) showed a strongly
reduced potency to activate MMTV-driven transcrip-
tion compared with wild type GR (Fig. 2). These data
are in line with the clinical observations concerning the
propositus, who had a 7-fold elevation of free serum
cortisol levels (7). However, this variant repressed
transcription from the PRL promoter nearly at wild
type levels (Fig. 3). This suggests that a different con-
formation of the GR is achieved when it is bound to an
nGRE or that a different conformation is necessary for
repression. The point mutation has an influence on the
effective conformation for transcriptional activation,
but not for this type of transcriptional repression.
GR has also been reported by several groups to play
a role in repressing transcription regulated by NF-kB
(23–25). NF-kB-responsive elements are required for
the function of many cytokine promoters as well as
other genes, including ICAM-1 (27, 28). A major form
of NF-kB is composed of a dimer of p50 and p65
(RelA) subunits, and this complex is retained in the
cytoplasm by repressor molecules that contain ankyrin
repeat motifs (27–29). Recently it was shown that a
large fraction of the NF-kB protein can be kept from
entering the nucleus by interacting with IkBa, the tran-
scription of which is stimulated by active GR (24, 25).
COS-1 cells lack endogenous IkBa activity (23), indi-
cating that in this system NF-kB is inactivated by a
direct interaction with GR, a mechanism that has been
postulated previously (23). The I559N and hGRb re-
ceptor variants did not inactivate NF-kB at all. The
capacity of the D641V variant to repress transcription
was increased, whereas the V729I variant repressed
slightly less efficiently as compared with the wild type
GR (Fig. 4). At lower receptor concentrations, this dif-
ference in repression was maintained. This indicates
that the binding capacities of the point mutants to p65
have not altered, but the conformation of the p65-GR
complex differs depending on the GR variant.
The transcription factor AP-1, consisting of het-
erodimers of the various members of the Fos and Jun
protein families, may play an essential role in convert-
ing extracellular signals into changes of the expression
of specific genes involved in inflammation as well as
cell growth and differentiation (for review see Refs. 30
and 31). AP-1 proteins share the bZIP-motif that al-
lows the formation of homodimeric complexes with
DNA. This motif is part of the target required for re-
pression (32). Both the Fos and Jun proteins are at the
receiving end of signal transduction pathways from the
cell membrane to the nucleus. GR synergizes with Jun
homodimers to activate AP-1 regulated promoters,
whereas it represses transcription induced by Fos-Jun
heterodimers without abolishing their binding to DNA
(33, 34). Unliganded GR is associated with heat shock
protein (hsp) 90 in the form of a heterohexamer con-
taining the receptor, two molecules of hsp 90, and one
molecule each of hsp 70, hsp 56, and hsp 26 (35–38).
The receptor is thus kept in a ligand-friendly confor-
mation. Ligand binding stimulates receptor activation,
dissociation from hsp 90 (39, 40), and nuclear trans-
location, prerequisites for both activation and repres-
sion of transcription. The general inactivation of AP-1
we observed suggests that weak association of the
ligand with the receptor is sufficient for dissociation of
the heat shock proteins and subsequent binding of the
receptor to AP-1. It has been shown that transcrip-
tional repression of the collagenase promoter also oc-
curs upon heat shock-induced nuclear import of GR in
transfected CV-1 cells, even without addition of hor-
mone (40). A receptor variant isolated from the human
leukemic cell line ICR27TK.3 (41), carrying a leucine to
phenylalanine change at position 753, which showed
14% hormone binding relative to the wild type GR,
was 100-fold less active in transcriptional activation
and did not reach wild type levels at 1027 M DEX.
However, it had full DEX-responsive AP-1-repressing
activity. In addition, heat shock treatment of cells
transfected with this variant resulted in full repression
in the absence of ligand (22). This suggests that, in
contrast to transcriptional activation, stably bound li-
gand is not necessary for transcriptional repression
once the receptor is in the nucleus. The I559N and the
hGRb variants have an intact DNA-binding domain,
which has been shown to be essential for inactivation
of AP-1, more so than is the hormone binding domain
(21). Interaction of GR with AP-1 in the cytoplasm
would explain why certain receptor variants such as
I559N and hGRb may repress the collagenase pro-
moter without stable ligand binding. It has been shown
that the in vivo AP-1 footprint does not disappear in
the presence of glucocorticoids (33), which would im-
ply that the putative cytoplasmic GR/AP-1 complex
does migrate into the nucleus and binds to AP-1 re-
sponse elements but has lost its capacity to activate
transcription. Because we have no indication for a
more efficient repression of AP-1 by any of the GR
variants we tested compared with the wild type GR, it
is conceivable that the complex resides on the target
promoter after inactivation by these variants. As is the
case for MMTV transcriptional activation, the reduced
transcriptional repression by the variants can directly
be associated with their reduced ligand binding
capacity.
The observed hormone-dependent induction of ac-
tivity of the ICAM-1 promoter as well as the collage-
nase promoter by the C467W/R479Q variant is puz-
zling. Because this induction was not seen in the
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absence of receptor (data not shown), the activation is
somehow brought about directly by this receptor vari-
ant. It could be that this variant in its active state forms
a complex with factors such as p65 or AP-1, thereby
allowing a better interaction with the regulatory ele-
ments on the DNA rather than preventing it.
From the differential response of NF-kB and AP-1 to
the variant receptors, one can conclude that different
GR mutations may cause strong phenotypic differ-
ences due to the differential association of the GR
mutants with several factors, which can either act as
coactivators (42) or corepressors (43, 44). Recently, a
protein representing the human homolog of the yeast
E2 ubiquitin-conjugating enzyme, Ubc9, has been re-
ported to interact with the wild type GR but not with
the inactive artificial GR mutant C476W/R479Q (44).
Furthermore, differences in phenotype between per-
sons carrying the same receptor variant may be due to
individual differences in the abundance and activity of
the GR-associating factors.
Taken together, our data point toward an explana-
tion as to why certain point mutations that reduce or
even impair the transcriptional activation capacity of
GR are not lethal to the subjects. Future research will
focus on factors associating with the receptor (e.g.
coactivators, corepressors as well as the hGRb iso-
form), determining the fine-tuning of gene regulation
that results in the observed variety of phenotypes.
MATERIALS AND METHODS
Materials
Dexamethasone was purchased from Pharmacin (Zwijn-
drecht, The Netherlands). 12-O-Tetradecanoylphorbol-13-
acetate (TPA) and D-luciferin were purchased from Sigma (St.
Louis, MO). The Renaissance chemiluminescence Western
blotting kit was obtained from Dupont NEN (Boston, MA).
Reporter Genes and Expression Vectors
Constructions of the majority of GR expression plasmids
used in this study were previously described: pRShGRa and
pRShGRb (26), which were kindly provided by Dr. Ronald
Evans (The Salk Institute, La Jolla, CA), pRShGRSer363 (9),
pRShGRAsn559 (10), and pRShGRVal641 (7). The pRSh-
GRIle729 expression plasmid (8) was a kind gift from Dr. Carl
Malchoff (Farmington, CT). pRShGRTrp476Gln479, contain-
ing a GR variant generated by Taq polymerase errors during
site-directed mutagenesis, which neither activates nor re-
presses transcription (21), was used as a control. In this
receptor variant, one of the coordinating cysteine residues in
the second Zn-cluster of the DNA binding domain at position
476 was converted into a tryptophan; furthermore, it contains
an arginine to glutamine change at position 479. This plasmid
was a kind gift from Dr. Andrew Cato (Forschungszentrum,
Karlsruhe, Germany). Construction of the plasmids
pRShGRLys23 and pRShGRVal641-II is described in the
following section.
The mouse mammary tumor virus-luciferase (MMTV-LUC)
reporter plasmid was kindly provided by Organon (Oss, The
Netherlands). The human collagenase 1-luciferase reporter
plasmid (COLL-LUC) was a kind gift from Dr. Andrew Cato.
The p65 expression plasmid was a kind gift from Prof. Carl
Scheidereit (Max-Delbru¨ck Center for Molecular Medicine,
Berlin, Germany). The human intercellular adhesion molecule
1-luciferase (ICAM-1-LUC) reporter plasmid pHBLUC1.3 was
kindly provided by Dr. Christian Stratowa (Bender & Co,
GmbH, Vienna, Austria), and the bovine PRL-luciferase re-
porter plasmid (PRL3-tk-LUC) was a kind gift from Dr. Sam
Okret (Huddinge Hospital, Huddinge, Sweden).
Construction of GR Plasmids
pRShGRLys23 was generated by overlap extension PCR
(46), to replace the guanosine (G) residues at cDNA positions
198 and 200 for adenosine (A) residues using the primers:
59-CCATTCACCACATTGGTGTG-39 (outer forward primer,
positioned 28 nucleotides (nt) 59 of the unique KpnI site),
59-TTGCCTGACAGTAAACTGTG-39 [outer reverse primer,
cDNA nt position 1025–1045, numbering according to Hol-
lenberg et al. (47)], 59-CACATCTCCCTTTTCCTGCG-39 (over-
lapping reverse primer, cDNA nt position 186–206), 59-TT-
GCCTGACAGTAAACTGTG-39 (overlapping forward primer,
cDNA nt position 191–211), and the pRShGRa expression
vector as a template. The G to A change at position 198 does
not give rise to an amino acid change, and the G to A change
at position 200 changes the arginine residue at codon 23 to
a lysine residue. The thymine (T) residue at position 192 was
replaced by a G residue to generate a CfoI restriction site,
without altering the encoded amino acid residue. The result-
ing fragment was digested with KpnI and SalI and was in-
serted into Bluescript plasmid (Stratagene, La Jolla, CA) di-
gested with the same enzymes. The fragment was fully
sequenced to confirm the presence of the desired point
mutations and to exclude additional point mutations. After
digestion of the recombinant plasmid with KpnI and SalI, the
recombinant fragment was ligated back into pRShGRa. The
expression vector obtained was confirmed by sequencing
and was designated pRShGRLys23.
The pRShGRVal641-II plasmid was constructed as
follows: The ClaI/XhoI fragment from the original
pRShGRVal641 plasmid was inserted into Bluescript plasmid
digested with the same enzymes. Similarly, the ClaI/XhoI
fragment from pRShGRa was inserted into Bluescript plas-
mid. This latter plasmid was digested with ClaI/SauI and
replaced with the ClaI/SauI recombinant fragment containing
the desired A to T change at cDNA position 2054 without any
further alterations. The ClaI/XhoI GR fragment containing the
single-point mutation was finally inserted to replace the wild
type fragment of pRShGRa. The resulting plasmid was
designated pRShGRVal641-II.
In the previous sections, GR variants encoded by these
plasmids have been referred to by their amino acid alter-
ations, indicated by single letter code.
Cell Culture and Transfections
Monkey kidney (COS-1) cells were maintained in DMEM-
Ham’s F-12 tissue culture medium (Life Technologies, Gaith-
ersburg, MD) supplemented with 5% charcoal dextran-
treated FCS (Life Technologies). For transcription regulation
studies, cells were plated at 1.0 3 105 cells per well (10 cm2),
grown for 24 h, and transfected overnight by calcium phos-
phate precipitation, as described previously (48). For MMTV-
LUC and COLL-LUC measurements, cells were transfected
with 250 ng GR expression plasmid and 250 ng reporter
plasmid per well. For PRL3-tk-LUC and ICAM 1-LUC mea-
surements, 500 ng GR expression plasmid and 1250 ng
reporter plasmid were added; in the ICAM-1 studies 75 ng
p65 expression plasmid were also added. pTZ carrier DNA
was added to a total amount of 5 mg DNA/well. After trans-
fection, experimental media were added. After an incubation
period of 24 h, cells were harvested for the LUC assay, as
described previously (49).
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Western Immunoblot Analysis
Whole-cell lysate was prepared by resuspending the cell
pellet from a well (10 cm2) in 200 ml 40 mM Tris-HCl, pH 7.4
(Boehringer, Mannheim, Germany), 1 mM EDTA, 10% (vol/vol)
glycerol, 1% (vol/vol) Triton X-100, 0.5% (wt/vol) sodium
deoxycholate, 0.08% (wt/vol) SDS (all from Merck, Amster-
dam, The Netherlands), 0.6 mM phenylmethylsulfonylfluoride
(Sigma), and 0.5 mM bacitracin (Aldrich, Axel, The Nether-
lands) at 4 C. The lysate was centrifuged (10 min, 1700 3 g),
and GR protein was immunoprecipitated from the superna-
tant using monoclonal antibody F52 (50) coupled to goat
anti-mouse agarose beads. Immunoprecipitated GR protein
was used for Western immunoblot analysis, essentially as
described previously (48). The polyclonal rabbit antiserum 57
(Affinity Bioreagents, Golden, CO) was used as the primary
antibody to identify the GR in a chemiluminescence protein
detection method, performed as described by the manufac-
turer (Dupont NEN).
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